| ［1］ |
Han B， Zheng R， Zeng H， et al. Cancer incidence and mortality in China， 2022［J］. J Natl Cancer Cent， 2024， 4（1）：47-53.
|
| ［2］ |
Browne IM， André F， Chandarlapaty S， et al. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer［J］. Lancet Oncol， 2024， 25（4）：e139-e151.
|
| ［3］ |
Xiao W，Zhang G， Chen B， et al. Mutational landscape of PI3K-AKTmTOR pathway in breast cancer： implications for targeted therapeutics［J］. J Cancer， 2021， 12（14）：4408-4417.
|
| ［4］ |
Jiang YZ，Ma D， Jin X， et al. Integrated multiomic profiling of breast cancer in the chinese population reveals patient stratification and therapeutic vulnerabilities［J］. Nat Cancer， 2024， 5（4）：673-690.
|
| ［5］ |
Martínez-Sáez O，Chic N，Pascual T，et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer［J］. Breast Cancer Res，2020， 22：45.
|
| ［6］ |
Nolan E， Lindeman GJ， Visvader JE. Deciphering breast cancer： from biology to the clinic［J］. Cell， 2023， 186（8）：1708-1728.
|
| ［7］ |
Pearson A，Proszek P， Pascual J， et al. Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance［J］. Clin Cancer Res， 2020， 26（3）：608-622.
|
| ［8］ |
Deng L， Zhu X， Sun Y， et al. Prevalence and prognostic role of PIK3CA/AKT1 mutations in chinese breast cancer patients［J］. Cancer Res Treat，2018，51（1）：128.
|
| ［9］ |
Wee P， Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways［J］. Cancers， 2017， 9（5）：52.
|
| ［10］ |
Ciruelos Gil EM.Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer［J］. Cancer Treat Rev， 2014， 40（7）：862-871.
|
| ［11］ |
Karami Fath M，Akhavan Masouleh R， Afifi N， et al. PI3K/AKT/mTOR signaling pathway modulation by circular RNAs in breast cancer progression［J］. Pathol Res Pract， 2023， 241：154279.
|
| ［12］ |
Chang WW， Lin RJ， Yu J， et al. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors［J］. Breast Cancer Res， 2013， 15（3）：R39.
|
| ［13］ |
Xu X，Zong Y， Gao Y， et al. VEGF induce vasculogenic mimicry of choroidal melanoma through the PI3k signal pathway［J］. BioMed Res Int， 2019， 2019：3909102.
|
| ［14］ |
Saatci O， Huynh-Dam KT， Sahin O. Endocrine resistance in breast cancer： from molecular mechanisms to therapeutic strategies［J］. J Mol Med Berl Ger， 2021， 99（12）：1691-1710.
|
| ［15］ |
Miller TW，Balko JM， Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer［J］. J Clin Oncol， 2011，29（33）：4452-4461.
|
| ［16］ |
McCartney A， Migliaccio I， Bonechi M， et al. Mechanisms of resistance to CDK4/6 inhibitors：potential implications and biomarkers for clinical practice［J］. Front Oncol， 2019， 9：666.
|
| ［17］ |
Jansen VM， Bhola NE， Bauer JA， et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer［J］. Cancer Res，2017， 77（9）：2488-2499.
|
| ［18］ |
Wilks ST.Potential of overcoming resistance to HER2-targeted therapies through the PI3K/akt/mTOR pathway［J］. Breast， 2015， 24（5）：548-555.
|
| ［19］ |
Berns K，Horlings HM， Hennessy BT， et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer ［J］. Cancer Cell， 2007，12（4）：395-402.
|
| ［20］ |
Eichhorn PJA， Gili M， Scaltriti M， et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235［J］. Cancer Res， 2008， 68（22）：9221-9230.
|
| ［21］ |
Hanker AB， Pfefferle AD， Balko JM， et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies［J］. Proc Natl Acad Sci， 2013， 110（35）：14372-14377.
|
| ［22］ |
Dey N， Williams C， Leyland-Jones B， et al. A critical role for HER3 in HER2-amplified and non-amplified breast cancers： function of a kinase-dead RTK［J］. Am J Transl Res， 2015， 7（4）：733.
|
| ［23］ |
Brown KK，Montaser-Kouhsari L， Beck AH， et al. MERIT40 is an akt substrate that promotes resolution of DNA damage induced by chemotherapy［J］. Cell Rep， 2015， 11（9）：1358-1366.
|
| ［24］ |
Gris-Oliver A， Ibrahim YH， Rivas MA， et al. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer［J］. Br J Cancer， 2021， 124（9）：1581.
|
| ［25］ |
Kathawala RJ，Gupta P， Ashby CR， et al. The modulation of ABC transporter-mediated multidrug resistance in cancer：a review of the past decade［J］. Drug Resist Updat， 2015， 18：1-17.
|
| ［26］ |
Sobhani N，Roviello G，Corona SP，et al. The prognostic value of PI3K mutational status in breast cancer：a meta-analysis［J］. J Cell Biochem，2018， 119（6）：4287-4292.
|
| ［27］ |
Rudolph M，Anzeneder T， Schulz A， et al. AKT1 E17K mutation profiling in breast cancer： prevalence， concurrent oncogenic alterations，and blood-based detection［J］. BMC Cancer，2016， 16（1）：622.
|
| ［28］ |
Li S，Shen Y， Wang M， et al. Loss of PTEN expression in breast cancer： association with clinicopathological characteristics and prognosis［J］. Oncotarget， 2017， 8（19）：32043-32054.
|
| ［29］ |
André F， Ciruelos EM， Juric D， et al. Alpelisib plus fulvestrant for PIK3CA-mutated， hormone receptor-positive， human epidermal growth factor receptor-2-negative advanced breast cancer： final overall survival results from SOLAR-1［J］. Ann Oncol， 2021， 32（2）：208-217.
|
| ［30］ |
Dumbrava EE， Call SG，Huang HJ，et al. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers［J］. ESMO Open，2021，6（5）：100230.
|
| ［31］ |
Rugo HS， André F， Yamashita T， et al. Time course and management of key adverse events during the randomized phase ⅢSOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer［J］. Ann Oncol， 2020， 31（8）：1001-1010.
|
| ［32］ |
Rugo HS， Lerebours F， Ciruelos E， et al. Alpelisib plus fulvestrant in PIK3CA-mutated， hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor （BYLieve）： one cohort of a phase 2，multicentre， open-label， non-comparative study［J］. Lancet Oncol，2021， 22（4）：489-498.
|
| ［33］ |
Jhaveri KL，Accordino MK， Bedard PL， et al. Phase I/ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA-mutated，hormone receptor-positive， human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer［J］. J Clin Oncol，2024：JCO2400110.
|
| ［34］ |
Turner NC，Im SA， Saura C， et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer［J］. N Engl J Med， 2024，391（17）：1584-1596.
|
| ［35］ |
Turner NC，Oliveira M， Howell SJ， et al. Capivasertib in hormone receptor-positive advanced breast cancer［J］. N Engl J Med， 2023，388（22）：2058.
|
| ［36］ |
Rugo HS，Oliveira M，Howell SJ，et al. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer：characterization， time course， and management of frequent adverse events from the phase ⅢCAPItello-291 study［J］. ESMO Open，2024，9（9）：103697.
|
| ［37］ |
Rugo HS， Oliveira M， Howell SJ， et al. Capivasertib and fulvestrant（F） for patients （pts） with aromatase inhibitor （AI）-resistant HR+/HER2- advanced breast cancer （ABC）： second progression-free survival（PFS2） and time to first subsequent chemotherapy （TFSC） in the CAPItello-291 trial［J］. ESMO Open，2024，9 Suppl 4：103205.
|
| ［38］ |
Zhang P，Xu B， Sun T， et al. A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies： a subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects［J］. Ann Oncol， 2024， 35 Suppl 2：S373-S374.
|
| ［39］ |
Baselga J， Campone M， Piccart M， et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer［J］. N Engl J Med，2012， 366（6）：520-529.
|
| ［40］ |
Piccart M， Hortobagyi GN， Campone M， et al. Everolimus plus exemestane for hormone-receptor-positive， human epidermal growth factor receptor-2-negative advanced breast cancer： overall survival results from BOLERO-2［J］. Ann Oncol， 2014， 25（12）：2357-2362.
|
| ［41］ |
Shao ZM，Cai L， Wang S， et al. BOLERO-5： a phase Ⅱstudy of everolimus and exemestane combination in chinese post-menopausal women with ER+/HER2- advanced breast cancer［J］. Discov Oncol，2024， 15（1）：237.
|
| ［42］ |
Kornblum N， Zhao F， Manola J， et al. Randomized phase Ⅱtrial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive， human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy： results of PrE0102［J］. J Clin Oncol， 2018， 36（16）：1556-1563.
|
| ［43］ |
Fan Y，Sun T， Shao Z， et al. Effectiveness of adding everolimus to the first-line treatment of advanced breast cancer in premenopausal women who experienced disease progression while receiving selective estrogen receptor modulators： a phase 2 randomized clinical trial［J］. JAMA Oncol， 2021， 7（10）：e213428.
|
| ［44］ |
Layman RM，Han HS， Rugo HS， et al. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptorpositive， HER2-negative advanced breast cancer： results from the dose expansion groups of an open-label， phase 1b study［J］. Lancet Oncol，2024， 25（4）：474-487.
|
| ［45］ |
Quintanilha J， Ross JS， Graf RP， et al. Genomic alterations （GA） in ESR1， PIK3CA， AKT1， and PTEN in HR（+）HER2（-） patients（pts） with metastatic breast cancer （MBC）： Co-occurrence and prevalence along treatment course.［J］. J Clin Oncol， 2024， 42（16）：1060.
|
| ［46］ |
Markou A，Farkona S， Schiza C， et al. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer［J］. Clin Cancer Res， 2014，20（22）：5823-5834.
|
| ［47］ |
中国抗癌协会肿瘤药物临床研究专业委员会， 国家肿瘤质控中心乳腺癌专家委员会， 中国抗癌协会肿瘤病理专业委员会， 等.PI3K/AKT/mTOR 信号通路抑制剂治疗乳腺癌临床应用专家共识［J］. 中华肿瘤杂志，2022，44（7）：673-692.
|
| ［48］ |
Burstein HJ， Somerfield MR， Barton DL， et al. Endocrine treatment and targeted therapy for hormone receptor-positive， human epidermal growth factor receptor 2-negative metastatic breast cancer： ASCO guideline update［J］. J Clin Oncol， 2021， 39（35）：3959-3977.
|
| ［49］ |
Burstein HJ， DeMichele A， Fallowfield L， et al. Endocrine and targeted therapy for hormone receptor-positive，human epidermal growth factor receptor 2-negative metastatic breast cancer-capivasertibfulvestrant： ASCO rapid recommendation update［J］. J Clin Oncol，2024， 42（12）：1450-1453.
|
| ［50］ |
Álvarez-Garcia V，Tawil Y， Wise HM， et al. Mechanisms of PTEN loss in cancer： it’s all about diversity［J］. Semin Cancer Biol， 2019， 59：66-79.
|
| ［51］ |
Khorasani ABS， Hafezi N， Sanaei MJ， et al. The PI3K/AKT/mTOR signaling pathway in breast cancer： review of clinical trials and latest advances［J］. Cell Biochem Funct， 2024， 42（3）：e3998.
|
| ［52］ |
Ge X，Behrendt CE， Yost SE， et al. Predicting hyperglycemia among patients receiving alpelisib plus fulvestrant for metastatic breast cancer［J］. Oncologist， 2023， 28（7）：e488-e492.
|
| ［53］ |
Bertucci A， Bertucci F， Gonçalves A. Phosphoinositide 3-kinase（PI3K） inhibitors and breast cancer： an overview of current achievements［J］. Cancers， 2023， 15（5）：1416.
|
| ［54］ |
André F， Ciruelos E， Rubovszky G， et al. Alpelisib for PIK3CAmutated， hormone receptor-positive advanced breast cancer［J］. N Engl J Med， 2019， 380（20）：1929-1940.
|
| ［55］ |
Neven P，Ciruelos EM， Lerebours F， et al. Alpelisib + endocrine therapy in patients with PIK3CA-mutated， hormone receptor-positive，human epidermal growth factor receptor 2-negative， advanced breast cancer： analysis of all 3 cohorts of the BYLieve study.［J］. J Clin Oncol， 2023，41（16）：1078.
|
| ［56］ |
Howell SJ，Casbard A， Carucci M， et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic， oestrogen receptor-positive， HER2-negative breast cancer（FAKTION）： overall survival， updated progression-free survival， and expanded biomarker analysis from a randomised， phase 2 trial［J］.Lancet Oncol， 2022， 23（7）：851-864.
|
| ［57］ |
Schmid P， Abraham J， Chan S， et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel As first-line therapy for metastatic triplenegative breast cancer： the PAKT trial［J］. J Clin Oncol， 2020，38（5）：423-433.
|
| ［58］ |
Dent R， Oliveira M， Isakoff SJ， et al. Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer［J］. Breast Cancer Res Treat，2021，189（2）：377-386.
|
| ［59］ |
Dent RA， Kim SB， Oliveira M， et al. Ipatasertib plus paclitaxel for patients with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer in the IPATunity130 phase Ⅲtrial［J］. Clin Cancer Res， 2024， 30（19）：4329-4338.
|
| ［60］ |
Yardley DA， Noguchi S， Pritchard KI， et al. Everolimus plus exemestane in postmenopausal patients with HR（+） breast cancer：BOLERO-2 final progression-free survival analysis ［J］. Adv Ther，2013， 30（10）：870-884.
|
| ［61］ |
Bachelot T， Bourgier C， Cropet C， et al. Randomized phase Ⅱtrial of everolimus in combination with tamoxifen in patients with hormone receptor-positive， human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors： a GINECO study［J］. J Clin Oncol， 2012， 30（22）：2718-2724.
|
| ［62］ |
Hurvitz SA，Andre F， Jiang Z， et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer （BOLERO-1）： a phase 3，randomised， double-blind， multicentre trial［J］. Lancet Oncol， 2015，16（7）：816-829.
|
| ［63］ |
André F，O’Regan R， Ozguroglu M， et al. Everolimus for women with trastuzumab-resistant， HER2-positive， advanced breast cancer（BOLERO-3）： a randomised， double-blind， placebo-controlled phase 3 trial［J］. Lancet Oncol， 2014， 15（6）：580-591.
|